Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 safety trial of meningococcal serogroup B rLP2086 vaccine in healthy participants aged 10 to <26 years
2009-015198-11Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of meningococcal group B recombinant lipoprotein 2086 vaccine in meningococcal disease (2 arms), sponsored by Pfizer. Primary endpoint: Percentage of subjects with at least one serious adverse event. Started Apr 2011; status: completed.
02
Drugs
meningococcal group B recombinant lipoprotein 2086 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2009-015198-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015198-11.